May 24, 2011Circulation
Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
Key result
Dabigatran 150 mg twice daily was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent.
Why the study?
Is dabigatran cost-effective compared to warfarin for stroke prophylaxis in patients with atrial fibrillation?
Population
Hypothetical cohort of 70-year-old patients with atrial fibrillation
Comparison
Dabigatran 150 mg twice daily, dabigatran 110… vs Warfarin
Design
Other
Authors
Discussion
Loading...
Member takes
Implication
May guide anticoagulation choice in high-risk AF with suboptimal INR control; leaves generalizability to current pricing open.
Structured PICO
Is dabigatran cost-effective compared to warfarin for stroke prophylaxis in patients with atrial fibrillation?
P
Population
Hypothetical cohort of 70-year-old patients with atrial fibrillation
I
Intervention
Dabigatran 150 mg twice daily, dabigatran 110 mg, aspirin, or dual therapy (aspirin and clopidogrel)
C
Comparator
Warfarin
O
Outcome
Cost and quality-adjusted survival (cost-effectiveness at $50,000/QALY threshold)
Dabigatran 150 mg twice daily is a cost-effective alternative to warfarin for stroke prophylaxis in atrial fibrillation patients with high stroke risk, provided warfarin INR control is not excellent.
Cite This Study
Shah et al. (2011) studied Atrial fibrillation. Dabigatran vs. Warfarin, aspirin, or dual therapy (aspirin and clopidogrel) was evaluated on Cost and quality-adjusted survival. Dabigatran 150 mg twice daily was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent.